Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 11, Issue 10, Pages 2144-2152Publisher
WILEY
DOI: 10.1111/j.1600-6143.2011.03643.x
Keywords
De novo; membranous nephropathy; PLA(2)R1; recurrent
Categories
Funding
- Agence de la Biomedecine
- Agence Nationale pour la Recherche [ANR-07-Physio-016-01]
- European Community [HEALTH-F2-2007-201590]
- Fondation pour la Recherche Medicale
- Association pour l'Utilisation du Rein Artificiel (AURA)
- Assistance Publique-Hopitaux de Paris
Ask authors/readers for more resources
Recent findings in idiopathic membranous nephropathy (MN) suggest that in most patients, the disease is because of anti-phospholipase A(2) receptor (PLA(2)R1) autoantibodies. Our aim was to analyze the prevalence and significance of anti-PLA(2)R1 antibodies in recurrent and de novo MN after transplantation. We assessed circulating PLA(2)R1 autoantibodies by a direct immunofluorescence assay based on human embryonic kidney cells transfected with a PLA(2)R1 cDNA, and the presence of PLA(2)R1 antigen in immune deposits. We showed that PLA(2)R1 was involved in 5 of 10 patients with recurrent MN, but in none of the 9 patients with de novo MN. We also showed a marked heterogeneity in the kinetics and titers of anti-PLA(2)R1, which may relate to different pathogenic potential. We provide evidence that some patients with PLA(2)R1-related idiopathic MN and anti-PLA(2)R1 antibodies at the time of transplantation will not develop recurrence. Because PLA(2)R1 autoantibody was not always associated with recurrence, its predictive value should be carefully analyzed in prospective studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available